WO2025077869 - ANTI-NY-ESO-1 ANTIBODIES AND USES THEREOF
National phase entry:
Publication Number
WO/2025/077869
Publication Date
17.04.2025
International Application No.
PCT/CN2024/124376
International Filing Date
12.10.2024
Title **
[English]
ANTI-NY-ESO-1 ANTIBODIES AND USES THEREOF
[French]
ANTICORPS ANTI-NY-ESO-1 ET LEURS UTILISATIONS
Applicants **
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Inventors
DU, Jun
ZHANG, Yue
ZHAO, Limin
DU, Pengfei
JIAO, Xin
ZHANG, Yuqi
Priority Data
PCT/CN2023/124435
13.10.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4633 | |
| EPO | Filing, Examination, Granting | 87634 | |
| Japan | Filing, Examination, Granting | 4591 | |
| South Korea | Filing, Examination, Granting | 7363 | |
| USA | Filing, Examination, Granting | 30190 |
Total:
134,411
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided are antibodies or antigen-binding fragments thereof that bind to a complex comprising a NY-ESO-1 peptide and an MHC molecule, the related antibody-drug conjugate (ADC) derived therefrom, chimeric antigen receptor (CAR) derived therefrom, T cell receptor (TCR) derived therefrom (e. g., a T cell mimic receptor), and the uses thereof.[French]
L'invention concerne des anticorps ou des fragments de liaison à l'antigène de ceux-ci qui se lient à un complexe comprenant un peptide NY-ESO-1 et une molécule CMH, un conjugué anticorps-médicament (ADC) associé ainsi dérivé, un récepteur antigénique chimérique (CAR) ainsi dérivé, un récepteur de lymphocyte T (TCR) ainsi dérivé (par exemple, un récepteur mimique de lymphocyte T), et leurs utilisations.